Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
Stock Snapshot
As of today, Neurocrine(NBIX) shares are valued at $167.40. The company's market cap stands at 16.94B, with a P/E ratio of 24.82.
On 2026-11-16, Neurocrine(NBIX) shares started trading at $169.96, with intraday highs of — and lows of —.
Trading volume for Neurocrine(NBIX) stock has reached 0, versus its average volume of 1.78M.
The stock's 52-week range extends from a low of $122.14 to a high of $186.12.
The stock's 52-week range extends from a low of $122.14 to a high of $186.12.
NBIX News
Neurocrine Biosciences (NBIX) announced an update on their ongoing clinical study. Study Overview: Neurocrine Biosciences’ official Phase 2 study, “A Prospecti...
Neurocrine Biosciences spent 2026 talking about concrete moves such as a US$2.9b cash deal for Soleno Therapeutics and fresh data readouts for CRENESSITY and VY...
Morgan Stanley raised the firm’s price target on Neurocrine (NBIX) to $191 from $185 and keeps an Equal Weight rating on the shares. The firm adjusted estimates...
Analyst ratings
86%
of 28 ratingsMore NBIX News
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX Quick QuoteNBIX - Free Report)...
Fresh data on patient reported outcomes for INGREZZA has pushed Neurocrine Biosciences (NBIX) back into focus for investors, as quality of life metrics intersec...
Neurocrine Biosciences ((NBIX)) has held its Q3 earnings call. Read on for the main highlights of the call. Neurocrine Biosciences delivered a strongly positiv...
Neurocrine Biosciences (NBIX Quick QuoteNBIX - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy)....
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.